儿童急性呼吸道博卡病毒感染

了解博卡病毒(Human Bocavirus,HBoV)在我国儿童急性呼吸道疾病中的感染情况。采用PCR扩增的方法对2005年10月~2006年1月收集的72例急性呼吸道感染的住院儿童鼻咽抽吸物(nasopharyngeal aspirates,NPA)进行了HBoV基因检测。将PCR阳性产物进行TA克隆,测序,并将所测序列与GenBank中HBoV序列进行比较分析。72份标本中共检测到6份HBoV阳性扩增产物,阳性率为8.3%(6/72),该6例HBoV阳性患儿临床均有肺炎或支气管肺炎症状。由此可以初步看出HBoV可能也是儿童急性呼吸道感染中较为重要的一个病原,且可能与儿童急性下呼吸道感染存在相关性。     

人博卡病毒I型的研究进展

人博卡病毒1型(HBoV1)为引发呼吸道感染一种新发病毒,具有典型的细小病毒科病毒基因组特征,3个开放阅读框分别编码非结构蛋白NS1、NP1和结构蛋白VP1和VP2;HBoV1进行滚环复制时存在复制环形附加体,附加体的发现为扩增HBoV1全基因组和构建感染性克隆拯救病毒提供可能,同时HBoV1与HBoV2-4间存在着重组关系;HBoV1的体外增殖随着三维立体细胞培养而成为现实,为HBoV1的致病机制研究提供有力平台。本文重点对HBoV1的分子生物学特征、疾病相关性、体外增殖培养、HBoV1的诊断和治疗进行阐述。     

兰州地区腹泻患儿中人博卡病毒1～4型流行病学研究

了解兰州地区病毒性腹泻患儿中人博卡病毒1~4型(HBoV1~4型)的流行情况及临床特点,并探讨HBoV与急性胃肠炎的疾病相关性。收集兰州大学第一医院2012年7月至2013年6月5岁以下腹泻患儿的粪便标本331份,采用PCR方法检测人博卡病毒,同时检测常见的肠道病毒。331份标本中共检出博卡阳性标本49例(14.80%),其中HBoV1~4型分别检测出26例、15例、7例和1例。分析其流行规律发现HBoV相关的腹泻全年散发,无明显季节分布。HBoV感染的患儿年龄为11.04±6.92月龄,高发年龄是7~12月龄。2岁以下患儿占HBoV阳性患儿总数的93.88%。HBoV与其他病毒混合感染率为71.3%,以混合轮状病毒为主。HBoV感染对腹泻患儿的发热和呕吐发生率无明显影响。检测出一例罕见的HBoV4病毒LZFB086,与泰国(序列号JQ267789)参考株的同源性为99.0%。未检测出HBoV2B型。从研究结果得出我国兰州地区人博卡病毒以HBoVl为主,在我国首次发现HBoV4病毒。HBoV1~4与其他病毒的混合感染率高,主要是混合轮状病毒。HBoV可能不是导致急性胃肠炎的致病病原。     

人博卡病毒及其在中国的流行现状

人博卡病毒(Human bocavirus,HBoV)属于细小病毒科,博卡病毒属。HBoV是除细小病毒B19和人细小病毒4(Human parvovirus,PARV4)外,目前所发现的与人类疾病有关的细小病毒之一。至今已有4种不同的HBoV相继报道,分别为HBoV1、HBoV2、HBoV3和HBoV4。HBoVs感染的发生率差异较大,且患者的临床表现各不相同,常与其它病原体共检出。本文就有关HBoVs的报道,从HBoVs的生物学性状、流行特征、致病机制、系统进化分析及其在我国的流行现状进行了阐述和讨论。     

猪博卡病毒的研究进展

猪博卡病毒是细小病毒科细小病毒亚科博卡病毒属的新成员,2009年发现于患仔猪断奶后多系统衰竭综合征的瑞典猪群中。目前,猪博卡病毒作为新发现的病原,已是世界各国科研人员的研究热点。本文结合已发表的文献,对猪博卡病毒的发现、分类、基因组结构与复制、流行病学、与疾病的相关性、培养与检测等方面进行了阐述,为广大科研人员对猪博卡病毒的研究提供一定的理论依据。     

人博卡病毒1型感染性克隆的构建及鉴定

人博卡病毒1 (human bocaparvovirus 1, HBoV1)为感染人并引起疾病的两种细小病毒之一。其感染2−5岁婴幼儿,能引起轻度或重度急性呼吸道疾病,严重时可危及生命。HBoV1基因组末端含末端反向重复序列(repeat the sequence in reverse, ITR),为病毒基因组复制所必需,但是难以进行PCR扩增合成。本研究通过分步合成末端ITR及分子克隆方法成功构建HBoV1的全长感染性克隆pSKHBoV1。经转染HEK293细胞后,分别从重要非结构蛋白的表达、病毒RNA转录后修饰与加工、病毒基因组复制水平以及子代病毒粒子基因组鉴定等方面,证实构建的感染性克隆在转染HEK293细胞后能够进入正常的复制周期并具有拯救出病毒粒子的潜力,这为后续研究HBoV1的复制增殖、病毒与宿主互作关系以及病毒疫苗的研发奠定了基础。     

人博卡病毒TaqMan探针实时定量PCR检测方法的建立及初步应用

目的:建立人博卡病毒(HBoV)核酸特异、快速、敏感的TaqMan探针实时定量PCR检测方法,并对临床样本进行检测。方法:比对编码HBoV非结构蛋白NP-1的基因序列,选取其保守片段设计引物和探针,建立实时荧光定量PCR检测方法,并与传统PCR方法进行比较,然后分别对两者的灵敏性、特异性、稳定性及临床样本检验的适用性等进行评价。结果:所建立的实时定量PCR检测方法可用于HBoV的特异性检测;相对于传统PCR所达到的250拷贝/反应的检测灵敏度,实时定量PCR的检测灵敏度可高达10拷贝/反应,检测范围为109～101拷贝/反应,且具有良好的特异性和重复性;初步用于76份临床呼吸道标本检测,检出阳性5例,高于普通PCR方法(3/76)。结论:建立了HBoV TaqMan探针实时定量PCR检测方法,并可用于临床鼻咽拭子样本的检测,为开展HBoV流行病学监测及早期临床诊断提供了技术手段。     

人博卡病毒编码蛋白功能研究

人博卡病毒(Human bocavirus,HBoV)是一类新发现的病毒,属于细小病毒科。至今己发现有4个基因型别(HBoV 1～4),不同基因型别的HBoV临床意义不同,有单一HBoV1感染致死的报道。但迄今为止,其复制机制、致病机理等尚不明确。HBoV基因组全长约为5.5kb,主要表达非结构蛋白NS1、NS2、NS3、NS4和NP1,以及结构蛋白VP1、VP2和VP3。本文旨在对近年来的HBoV各编码蛋白功能研究进展进行综述,并对HBoV未来可能的研究方向进行展望。     

WLL-1株博卡病毒(Bocavirus)全基因组序列分析

儿童下呼吸道感染已成为当前儿科发病率最高的一种疾病,而病毒是小儿下呼吸道感染的重要原因。临床上有相当比例的小儿下呼吸道感染病因未能作出明确的实验室诊断,给临床诊断与治疗带来了较大的困难。小儿下呼吸道感染可以由不同病毒引起,其中包括呼吸道合胞病毒、流感病毒、腺     

人博卡病毒基因克隆及衣壳编码基因序列变异分析

为了解人博卡病毒(Human Bocavirus,HBoV)VP1基因进化关系;阐明HBoV目前具体的变化规律,用PCR的方法扩增了1株HBoV的全基因和9株HBoV的VP1基因,克隆并测序,在此基础上,将HBoV的全基因序列和衣壳序列分别与细小病毒亚科其他14个有代表性的病毒进行遗传分析,构建进化树,对目前所有可得到的HBoV的17个衣壳蛋白进行二级结构分析和抗原性分析。结果显示:HBoV全基因序列与B19关系较远,但衣壳序列遗传关系较近。以有典型性的猫瘟细小病毒(Feline parvovirus,FPV)衣壳蛋白为参照,分析多个HBoV衣壳序列之间的变异情况,显示HBoV衣壳的二级结构基础表现出较高的保守性,序列之间的变化主要发生在高抗原区域和感染活性区域。衣壳病毒变异情况显示HBoV在稳定自身的情况下表现出一定的活跃性以逃避免疫反应,也表现出一定的感染适应力。     

Bocavirus Infection in Otherwise Healthy Children with Respiratory Disease

To evaluate the role of human bocavirus (hBoV) as a causative agent of respiratory disease, the importance of the viral load in respiratory disease type and severity and the pathogenicity of the different hBoV species, we studied all hBoV-positive nasopharyngeal samples collected from children who attended an emergency room for a respiratory tract infection during three winters (2009–2010, 2011–2012, and 2013–2014). Human bocavirus was detected using the respiratory virus panel fast assay and real-time PCR. Of the 1,823 nasopharyngeal samples, 104 (5.7%) were positive for hBoV; a similar prevalence was observed in all three periods studied. Among hBoV-infected children, 53.8% were between 1–2 years old, and hBoV was detected alone in 57/104 (54.8%) cases. All of the detected hBoV strains belonged to genotype 1. The median hBoV load was significantly higher in samples containing strains with both the N546H and T590S mutations compared to other samples (p<0.05). Children with a single hBoV-1 infection more frequently had upper respiratory tract infections (URTIs) than those who were co-infected (37.0% vs 17.8%, respectively, p = 0.04). The duration of hospitalization was longer among children with high viral loads than that observed among children with low viral loads (8.0 ±2.2 days vs 5.0 ±1.5 days, respectively, p = 0.03), and the use of aerosol therapy was more frequent among children with high viral loads than among those with low viral loads (77.1% vs 55.7%, respectively, p = 0.04). This study shows that hBoV is a relatively uncommon but stable infectious agent in children and that hBoV1 seems to be the only strain detected in Italy in respiratory samples. From a clinical point of view, hBoV1 seems to have in the majority of healthy children relatively low clinical relevance. Moreover, the viral load influences only the duration of hospitalization and the use of aerosol therapy without any association with the site of the respiratory disease.     

Surveillance and Genome Analysis of Human Bocavirus in Patients with Respiratory Infection in Guangzhou, China

Human bocavirus (HBoV) is a novel parvovirus associated with respiratory tract diseases and gastrointestinal illness in adult and pediatric patients throughout the world. To investigate the epidemiological and genetic variation of HBoV in Guangzhou, South China, we screened 3460 throat swab samples from 1686 children and 1774 adults with acute respiratory infection symptoms for HBoV between March 2010 and February 2011, and analyzed the complete genome sequence of 2 HBoV strains. Specimens were screened for HBoV by real-time PCR and other 6 common respiratory viruses by RT-PCR or PCR. HBoV was detected in 58 (1.68%) out of 3460 samples, mostly from pediatric patients (52/58) and inpatient children (47/58). Six adult patients were detected as HBoV positive and 5 were emergency cases. Of these HBoV positive cases, 19 (32.76%) had co-pathogens including influenza virus (n = 5), RSV (n = 5), parainfluenza (n = 4), adenovirus (n = 1), coronavirus (n = 7). The complete genome sequences of 2 HBoVs strains (Genbank no. {"type":"entrez-nucleotide","attrs":{"text":"JN794565","term_id":"361064618","term_text":"JN794565"}}JN794565 and {"type":"entrez-nucleotide","attrs":{"text":"JN794566","term_id":"361064623","term_text":"JN794566"}}JN794566) were analyzed. Phylogenetic analysis showed that the 2 HBoV strains were HBoV1, and were most genetically close to ST2 (GenBank accession number DQ0000496). Recombination analysis confirmed that HBoV strain GZ9081 was an intra–genotype recombinant strain among HBoV1 variants.     

人乳头瘤病毒结构蛋白在病毒感染中的作用研究进展

人乳头瘤病毒(Human papillomavirus,HPV)属于乳多空病毒科(Papovaviridae)的乳头瘤病毒属,是一种无包膜的双链DNA病毒,能诱发人的皮肤或粘膜产生疣和乳头状瘤,某些基因型与子宫颈癌密切相关.     

人微小病毒B19感染的研究进展

近年来人微小病毒B19(human parvovirus B19)作为人类疾病的重要病原已愈来愈广泛受到重视。大量研究成果不但揭示了B19病毒的致病机理,Th-1介导的细胞免疫应答,而且发展了B19感染的诊断和B19污染血制品的筛查技术,并且为疫苗的研制奠定了基础。这里对人类B19病毒的病原学特征、致病机理、临床症状及实验室诊断方法和技术进行了较全面的综述。     

Widespread Infection with Homologues of Human Parvoviruses B19, PARV4, and Human Bocavirus of Chimpanzees and Gorillas in the Wild

Infections with human parvoviruses B19 and recently discovered human bocaviruses (HBoVs) are widespread, while PARV4 infections are transmitted parenterally and prevalent specifically in injecting drug users and hemophiliacs. To investigate the exposure and circulation of parvoviruses related to B19 virus, PARV4, and HBoV in nonhuman primates, plasma samples collected from 73 Cameroonian wild-caught chimpanzees and gorillas and 91 Old World monkey (OWM) species were screened for antibodies to recombinant B19 virus, PARV4, and HBoV VP2 antigens by enzyme-linked immunosorbent assay (ELISA). Moderate to high frequencies of seroreactivity to PARV4 (63% and 18% in chimpanzees and gorillas, respectively), HBoV (73% and 36%), and B19 virus (8% and 27%) were recorded for apes, while OWMs were uniformly negative (for PARV4 and B19 virus) or infrequently reactive (3% for HBoV). For genetic characterization, plasma samples and 54 fecal samples from chimpanzees and gorillas collected from Cameroonian forest floors were screened by PCR with primers conserved within Erythrovirus, Bocavirus, and PARV4 genera. Two plasma samples (chimpanzee and baboon) were positive for PARV4, while four fecal samples were positive for HBoV-like viruses. The chimpanzee PARV4 variant showed 18% and 15% nucleotide sequence divergence in NS and VP1/2, respectively, from human variants (9% and 7% amino acid, respectively), while the baboon variant was substantially more divergent, mirroring host phylogeny. Ape HBoV variants showed complex sequence relationships with human viruses, comprising separate divergent homologues of HBoV1 and the recombinant HBoV3 species in chimpanzees and a novel recombinant species in gorillas. This study provides the first evidence for widespread circulation of parvoviruses in primates and enables future investigations of their epidemiology, host specificity, and (co)evolutionary histories.Autonomous parvoviruses known to infect humans comprise parvovirus B19 (18) and the recently discovered PARV4 (22) and human bocavirus (HBoV) (3). Members of the family Parvoviridae are genetically and biologically diverse and are classified into several genera or groups, showing marked differences in host range, pathology, and tissue/cellular tropisms (18). Human parvovirus B19, a member of the Erythrovirus genus, is transmitted primarily by the respiratory route but causes systemic infections. Erythroid progenitor cells are specifically targeted through expression of globoside P antigen, which acts as the B19 virus receptor for entry (5). In common with infections by most parvoviruses, B19 virus infections are acute; a period of intense viremia is followed by seroconversion for antibody to B19 virus and lifelong immunity from reinfection (29). Despite the clearance of viremia and seroconversion for antibody, lifelong persistence of viral DNA in tissues has been shown to occur (12, 20, 26, 28, 43, 58). Three genotypes of B19 virus have been described, differing in nucleotide sequence by approximately 13 to 14% (7, 21, 41, 53); genotypes 1 and 2 have been found in Europe, the United States, and other Western countries, while genotype 3 is restricted to sub-Saharan Africa and South America (7, 47, 49). B19 virus widely circulates in human populations worldwide; in Western countries, several studies have documented increasing frequencies of B19 virus seropositivity with age, rising to approximately 60 to 70% by adulthood (15, 39, 48, 61).Another human parvovirus, PARV4, shows markedly different epidemiology and transmission routes. It was originally detected in plasma from an individual with an “acute infection syndrome” resembling that of primary human immunodeficiency virus (HIV) infection (22). While this clinical presentation has not been observed again, infection with PARV4 is known to be widespread specifically in individuals with a history of parenteral exposure (injecting drug users [IDUs], hemophiliacs, polytransfused individuals), with a strikingly higher incidence in those infected with HIV-1 (13, 14, 30, 35, 54). These observations suggest that PARV4 is primarily transmitted though parenteral routes in Western countries (54, 56). In common with infection with the better-characterized human parvovirus B19, infection with PARV4 is associated with a period of acute viremia, followed by seroconversion for antibody and long-term persistence of viral DNA sequences in lymphoid and other tissue (33, 37, 52). Circulating variants of PARV4 have been classified into three distinct genotypes exhibiting approximately 8% nucleotide sequence divergence from each other. Genotypes 1 and 2 circulate in Western countries, while genotype 3 has to date been recorded only in sub-Saharan Africa (45, 55).The third human parvovirus, HBoV (3), shows a number of epidemiological and clinical attributes different from those of both B19 virus and PARV4. HBoV was originally found in the respiratory tract of young children and has been the subject of intense investigation as a potential cause of human respiratory disease (reviewed in references 1, 51, and 62). Although it is frequently detected by PCR in the nasopharynx of viremic individuals with primary infections with lower respiratory tract disease, other coinfecting respiratory viruses are frequently detected (19). HBoV additionally shows long-term, low-level carriage in the respiratory tract after primary infection, which further complicates PCR-based etiological studies (2, 38) and warrants the use of other diagnostic strategies, such as serology (30, 32, 59). In contrast to the rather minimal genetic diversity of B19 virus and PARV4 genotypes, bocaviruses infecting humans are now known to comprise three to four major genetic variants (termed types or species 1 to 4) (23, 24). HBoV1 and HBoV2 show 22%, 33%, and 20% amino acid sequence divergence from each other in the encoded viral nonstructural (NS), NP-1, and structural VP1/VP2 proteins, respectively, the latter potentially leading to antigenic diversity and some loss of antigenic cross-reactivity. A third type/species of HBoV is a chimeric form with a nonstructural gene region (NS, NP1) most similar to HBoV1, a recombination breakpoint in the intergenic region between NP1 and VP1, and structural genes related to those of HBoV2 (4, 23). Current data suggest that only HBoV1 is capable of infecting the respiratory tract; most published large-scale screening studies have failed to detect HBoV2 (or HBoV3) in respiratory samples (10, 11, 60), while all three types/species are detectable in fecal samples, indicating the existence of an alternative or additional site of virus replication (23). Despite extensive inquiry, the exact role of HBoV1 in respiratory disease remains unclear, as is the proposed etiological role of HBoV2 (and possibly HBoV3) in gastroenteritis (4, 11, 23, 50). Very recently, a fourth species/type, HBoV4, has been detected in fecal samples; genetically it also shows evidence for past recombination, with NS and NP1 region sequences grouping with HBoV2, while VP1/VP2 is more closely related to HBoV3 (23).We have little understanding of the past epidemiology, evolution, and origins of human parvoviruses. For both B19 virus and PARV4, evidence has been obtained for a temporal succession of genotypes over time (37, 43); in Europe, B19 virus genotype 1 largely replaced type 2 in the 1960 and 1970s (43), while current data indicate that a similar replacement of PARV4 genotypes occurred within the last 20 years (37). The highly restricted sequence diversity of currently circulating variants of PARV4 and B19 virus and of HBoV1 variants supports the hypothesis of a relatively recent emergence and spread of these viruses in human populations (36, 42, 64).The existence and evolution of parvoviruses on a much longer time scale is suggested by the observations that members of the Erythrovirus and Parvovirus genera both contain viruses that are highly host species specific and that the molecular phylogenies of both genera are largely congruent with those of their hosts (34). This has led to the hypothesis of long-term coevolution of parvoviruses with their host over the 90 million years of mammalian evolution and perhaps beyond. Among erythroviruses, simian homologues of B19 virus have been found in cynomolgus monkeys (44) and rhesus and pig-tailed macaques (16) and more genetically distant viruses have been characterized in chipmunks and cows (9, 63). Divergent homologues of PARV4 in pigs and cows have been described (31), while the bovine and canine parvoviruses distantly related to HBoV are the originally described members of the Bocavirus genus. However, the process of virus-host codivergence is known to be punctuated by occasional cross-species transmissions, including the well-documented spread of feline parvovirus to dogs (46). Based on serological evidence, the possible transmission of simian erythroviruses to animal handlers has been proposed (6).To gain further insights into the origins and evolution of human parvoviruses, we have performed large-scale serological and PCR-based screening of nonhuman primates (chimpanzees and gorillas) and of several species of Old World monkeys (OWMs) for evidence of infection with parvoviruses that are antigenically related to the human B19, PARV4, and HBoV viruses. By PCR, we have sought to genetically characterize homologues of the three autonomous human parvoviruses in apes and Old World monkey species and to analyze their evolutionary relationship to human and other mammalian homologues of these viruses.